The results of the MIRACLE study are awaited regarding the efficacy and safety of the non-steroidal MR antagonist Balcinrenone in combination with dapagliflozin in patients with HF and CKD, compared with dapagliflozin alone [90]. This evidence concerns the gene NR3C2 and chronic kidney disease.